» Articles » PMID: 27756415

Borderline Ovarian Tumors: Clinical Characteristics, Management, and Outcomes - a Multicenter Study

Abstract

Background: The optimal surgical management and staging of borderline ovarian tumors (BOTs) are controversial. Institutions have different surgical approaches for the treatment of BOTs. Here, we performed a retrospective review of clinical characteristics, surgical management and surgical outcomes, and sought to identify variables affecting disease-free survival (DFS) and overall survival (OS) in patients with BOTs.

Methods: A retrospective review of ten gynecological oncology department databases in Turkey was conducted to identify patients diagnosed with BOTs. The effects of type of surgery, age, stage, surgical staging, complete versus incomplete staging, and adjuvant chemotherapy were examined on DFS and OS.

Results: In total, 733 patients with BOTs were included in the analysis. Most of the staged cases were in stage IA (70.4 %). In total, 345 patients underwent conservative surgeries. Recurrence rates were similar between the conservative and radical surgery groups (10.5 % vs. 8.7 %). Furthermore we did not find any difference between DFS (HR = 0.96; 95 % confidence interval, CI = 0.7-1.2; p = 0.576) or OS (HR = 0.9; 95 % CI = 0.8-1.1; p = 0.328) between patients who underwent conservative versus radical surgeries. There was also no difference in DFS (HR = 0.74; 95 % CI = 0.8-1.1; p = 0.080) or OS (HR = 0.8; 95 % CI = 0.7-1.0; p = 0.091) between complete, incomplete, and unstaged patients. Furthermore, receiving adjuvant chemotherapy (CT) for tumor stage ≥ IC was not an independent prognostic factor for DFS or OS.

Conclusions: Patients undergoing conservative surgery did not show higher recurrence rates; furthermore, survival time was not shortened. Detailed surgical staging, including lymph node sampling or dissection, appendectomy, and hysterectomy, were not beneficial in the surgical management oF BOTs.

Citing Articles

A giant ovarian atypical proliferative mucinous tumor in a young adult: A rare case report and review of the literature.

Mesarieki L, Macheku G, Kayombo G, Minga B, Sadiq A, Mremi A Int J Surg Case Rep. 2024; 126():110753.

PMID: 39700580 PMC: 11718320. DOI: 10.1016/j.ijscr.2024.110753.


Laparoscopic Fertility-Sparing Management of Borderline Ovarian Tumors: Surgical and Long-Term Oncological Outcomes.

Tortajada Valle M, Agusti N, Fuste P, Mension E, Diaz-Feijoo B, Glickman A J Clin Med. 2024; 13(18).

PMID: 39336945 PMC: 11432542. DOI: 10.3390/jcm13185458.


Is There Re-staging Surgery Necessity for Borderline Ovarian Tumors.

Guo L, Kang X, Su Y, Liu X, Wu X, Xie W Curr Med Sci. 2023; 43(4):822-830.

PMID: 37455277 DOI: 10.1007/s11596-023-2775-9.


A retrospective analysis of relapse-related factors for ovarian borderline tumors.

Ye D, Shen H, Huang W, Yao L Am J Transl Res. 2022; 14(8):5712-5718.

PMID: 36105008 PMC: 9452353.


Second fertility-sparing surgery and fertility-outcomes in patients with recurrent borderline ovarian tumors.

Wang L, Zhong Q, Tang Q, Wang H Arch Gynecol Obstet. 2022; 306(4):1177-1183.

PMID: 35396974 PMC: 9470715. DOI: 10.1007/s00404-022-06431-5.


References
1.
Desfeux P, Camatte S, Chatellier G, Blanc B, Querleu D, Lecuru F . Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol. 2005; 98(3):390-5. DOI: 10.1016/j.ygyno.2005.04.043. View

2.
Gotlieb W, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E . Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005; 97(3):780-3. DOI: 10.1016/j.ygyno.2005.02.022. View

3.
Boran N, Cil A, Tulunay G, Ozturkoglu E, Koc S, Bulbul D . Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol. 2005; 97(3):845-51. DOI: 10.1016/j.ygyno.2005.03.010. View

4.
Ren J, Peng Z, Yang K . A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol Oncol. 2008; 110(2):162-7. DOI: 10.1016/j.ygyno.2008.03.019. View

5.
Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E . Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer. 2004; 100(6):1145-51. DOI: 10.1002/cncr.20098. View